An interventional study of Urotronic Drug Coated Balloon (DCB) in Urethral Stricture, sponsored by Urotronic Inc.. Completed at 5 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Urotronic Inc. · Not applicable, Interventional, and Device feasibility
The study described below is designed to assess the safety and device performance for the drug coated balloon (DCB) for the treatment of urethral stricture.
72 studies on the registry are indexed under Urethral Stricture; 25 are open to participants now.
This study's enrollment of 16 is below the median of 60 across 56 interventional studies indexed under Urethral Stricture.
Browse Urethral Stricture studies →Urotronic Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Up to 15 subjects will be enrolled and treated with the Urotronic drug coated balloon (DCB)
Device: Urotronic Drug Coated Balloon (DCB)
The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
Safety- Rate of Device Related Serious Complications
Time frame: 90 days
Safety- Change in IIEF (International Index of Erectile Function)
Time frame: 90 days
Efficacy- Stricture Recurrence Rate
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Urotronic Inc.